ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
종양용해성 아데노바이러스 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 루스 공학의 기술 진보, 종양학 연구에 대한 투자 증가에 기인한다고 생각됩니다.주요 동향으로서는 바이러스 공학 기술의 진보, 혁신적인 드러그 딜리버리 시스템, 종양을 표적으로 한 정밀도의 향상, 선진적인 면역 치료의 병용, 환자의 모니터링과 진단의 강화 등을 들 수 있습니다.
암 이환율의 상승은 향후 몇 년간의 종양용해성 아데노바이러스 시장의 확대를 견인할 것으로 예측됩니다. 걸음 등의 요인이 암 증례 증가에 기여하고 있습니다. 곳(NCI)은 세계에서 약 2,000만명의 신규암 환자와 970만명의 사망자를 보고하고, 2040년의 예측은 2,990만명의 환자수와 1,530만명의 사망자수로 상승한다고 했습니다. 계국에 따르면, 2023년에는 호주인의 1.8%가 암에 걸려, 특히 75세 이상에서는 남성(2.1%)의 이환율이 여성(1.6%)을 약간 웃돌고 있습니다. 그 결과, 암 이환율 증가가 종양용해성 아데노바이러스 시장의 성장을 뒷받침하고 있습니다.
종양용해성 아데노바이러스 시장에서 사업을 전개하는 기업은 종양의 표적성을 높이고 치료 성적을 향상시키기 위해 온콜리틱 바이러스 치료과 화학치료을 통합한 VCN-01과 같은 병용 치료에 주력하고 있습니다. 01은 암세포에 선택적으로 감염하여 파괴함과 동시에 화학치료의 효과를 높이기 위해 고안된 종양용해성 아데노바이러스입니다. Biologics는 미국 식품의약국(FDA)이 이 회사의 주요 후보인 VCN-01에 Fast Track Designation(FTD)을 부여했다고 발표했습니다. VCN-01은 종양 세포 내에서 복제되어 효과적인 암 치료의 중요한 장벽인 종양 간질 파괴를 돕습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 종양용해성 아데노바이러스 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 종양용해성 아데노바이러스 시장 : 성장률 분석
세계의 종양용해성 아데노바이러스 시장 실적 : 규모와 성장(2019-2024년)
세계의 종양용해성 아데노바이러스 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 종양용해성 아데노바이러스 총 시장 규모(TAM)
제6장 시장 세분화
세계의 종양용해성 아데노바이러스 시장 : 바이러스유 형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
아데노바이러스 5형 기반 종양 용해성 바이러스
아데노바이러스 2형 기반 종양 용해성 바이러스
기타 바이러스의 유형
세계의 종양용해성 아데노바이러스 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
흑색종
전립선암
유방암
난소암
폐암
기타 용도
세계의 종양용해성 아데노바이러스 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
암 연구기관
바이오테크놀러지 기업
학술연구기관
세계의 종양용해성 아데노바이러스 시장 : 아데노바이러스 5형 기반 종양 용해성 바이러스 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제1세대 아데노바이러스 5형 기반
제2세대 아데노바이러스 5형 기반
유전자 변형 아데노바이러스 5형 기반
세계의 종양용해성 아데노바이러스 시장 : 아데노바이러스 2형 기반 종양 용해성 바이러스 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제1세대 아데노바이러스 2형 기반
제2세대 아데노바이러스 2형 기반
유전자 변형 아데노바이러스 2형 기반
세계의 종양용해성 아데노바이러스 시장 : 기타 바이러스 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
변형 아데노바이러스 균주
하이브리드 아데노바이러스 유형
키메라 아데노바이러스
제7장 지역별 및 국가별 분석
세계의 종양용해성 아데노바이러스 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 종양용해성 아데노바이러스 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
종양용해성 아데노바이러스 시장 : 경쟁 구도
종양용해성 아데노바이러스 시장 : 기업 프로파일
Amgen Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Targovax ASA 개요, 제품 및 서비스, 전략 및 재무 분석
CG Oncology Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Replimune Group Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Imugene Limited 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Oncorus Inc.
PsiOxus Therapeutics Ltd.
Vyriad Inc.
Transgene SA
Valo Therapeutics Oy
EpicentRx Inc.
DNAtrix Inc.
Shanghai Sunway Biotech Co. Ltd.
TILT Biotherapeutics Ltd.
Oncolys BioPharma Inc.
Lokon Pharma AB
GeneMedicine Co. Ltd.
Akamis Bio Ltd.
Genelux Corporation
SillaJen Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
종양용해성 아데노바이러스 시장(2029년) : 새로운 기회를 제공하는 국가
종양용해성 아데노바이러스 시장(2029년) : 새로운 기회를 제공하는 부문
종양용해성 아데노바이러스 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Oncolytic adenovirus is a genetically modified virus designed to selectively target and destroy cancer cells while preserving healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which continue attacking the cancer. Additionally, it stimulates the immune system, enhancing the body's anti-tumor response.
The primary types of oncolytic adenoviruses include adenovirus type 5-based oncolytic viruses, adenovirus type 2-based oncolytic viruses, and other variants. Adenovirus type 5-based oncolytic viruses are genetically engineered to selectively infect and destroy cancer cells while sparing normal tissues. These viruses are used in the treatment of melanoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, and other malignancies. End-users include hospitals, cancer research institutes, biotechnology companies, and academic and research institutions.
The oncolytic adenovirus market research report is one of a series of new reports from The Business Research Company that provides oncolytic adenovirus market statistics, including the oncolytic adenovirus industry global market size, regional shares, competitors with the oncolytic adenovirus market share, detailed oncolytic adenovirus market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic adenovirus industry. This oncolytic adenovirus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oncolytic adenovirus market size has grown strongly in recent years. It will grow from $122.31 billion in 2024 to $132.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the rising prevalence of cancer, increasing demand for targeted cancer therapies, growing R&D funding, advancements in delivery methods, and regulatory approvals.
The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $183.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to the rising prevalence and incidence of cancer, the expansion of combination therapies, regulatory advancements and approvals, technological progress in virus engineering, and increased investment in oncology research. Key trends include advancements in viral engineering techniques, innovative drug delivery systems, improved tumor-targeting precision, advanced immunotherapy combinations, and enhanced patient monitoring and diagnostics.
The rising incidence of cancer is expected to drive the expansion of the oncolytic adenovirus market in the coming years. Cancer is a disease characterized by uncontrolled cell growth and its spread to other parts of the body. Factors such as aging populations, lifestyle choices, environmental exposures, genetic predispositions, and advancements in detection contribute to the increasing number of cancer cases. Oncolytic adenoviruses selectively target and destroy cancer cells, presenting a promising therapeutic approach to addressing this growing health challenge. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australia-based government agency, reported that 1.8% of Australians had cancer, with males (2.1%) being slightly more affected than females (1.6%), particularly among those aged 75 and older. As a result, the increasing incidence of cancer is fueling growth in the oncolytic adenovirus market.
Companies operating in the oncolytic adenovirus market are focusing on combination therapies such as VCN-01, which integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to selectively infect and destroy cancer cells while also increasing the efficacy of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. The oncolytic adenovirus VCN-01 replicates within tumor cells, helping to break down the tumor stroma, a significant barrier to effective cancer treatment.
In March 2022, Synthetic Biologics, Inc., a US-based biotechnology company, acquired VCN Biosciences for an undisclosed sum. This acquisition strengthens its drug development pipeline by incorporating VCN's clinical-stage drug VCN-01 and preclinical candidate VCN-11, both of which are oncolytic adenoviruses designed to target cancers with high unmet medical needs. VCN Biosciences, S.L. (VCN) is a Spain-based biotechnology company specializing in the development of oncolytic adenoviruses for cancer treatment.
Major players in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, and SillaJen Inc.
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oncolytic adenovirus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the oncolytic adenovirus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The oncolytic adenovirus market consists of revenues earned by entities by providing services such as virus engineering and customization, clinical trial management, regulatory consulting, and contract research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncolytic adenovirus market also includes sales of therapies, customized viral vectors, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oncolytic Adenovirus Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oncolytic adenovirus market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oncolytic adenovirus ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncolytic adenovirus market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses; Adenovirus Type 2-Based Oncolytic Viruses; Other Virus Types
2) By Application: Melanoma; Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Other Applications
3) By End-User: Hospitals; Cancer Research Institutes; Biotechnology Companies; Academic And Research Institutes
Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based; Second-generation Adenovirus Type 5-based; Engineered Adenovirus Type 5-based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based; Second-generation Adenovirus Type 2-based; Engineered Adenovirus Type 2-based
3) By Other Virus Types: Modified Adenovirus Strains; Hybrid Adenovirus Types; Chimeric Adenoviruses
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Oncolytic Adenovirus Market Characteristics
3. Oncolytic Adenovirus Market Trends And Strategies
4. Oncolytic Adenovirus Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Oncolytic Adenovirus Growth Analysis And Strategic Analysis Framework
5.1. Global Oncolytic Adenovirus PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oncolytic Adenovirus Market Growth Rate Analysis
5.4. Global Oncolytic Adenovirus Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oncolytic Adenovirus Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oncolytic Adenovirus Total Addressable Market (TAM)
6. Oncolytic Adenovirus Market Segmentation
6.1. Global Oncolytic Adenovirus Market, Segmentation By Virus Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenovirus Type 5-Based Oncolytic Viruses
Adenovirus Type 2-Based Oncolytic Viruses
Other Virus Types
6.2. Global Oncolytic Adenovirus Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Other Applications
6.3. Global Oncolytic Adenovirus Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Institutes
Biotechnology Companies
Academic And Research Institutes
6.4. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Adenovirus Type 5-Based Oncolytic Viruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-generation Adenovirus Type 5-based
Second-generation Adenovirus Type 5-based
Engineered Adenovirus Type 5-based
6.5. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Adenovirus Type 2-Based Oncolytic Viruses, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-generation Adenovirus Type 2-based
Second-generation Adenovirus Type 2-based
Engineered Adenovirus Type 2-based
6.6. Global Oncolytic Adenovirus Market, Sub-Segmentation Of Other Virus Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Modified Adenovirus Strains
Hybrid Adenovirus Types
Chimeric Adenoviruses
7. Oncolytic Adenovirus Market Regional And Country Analysis
7.1. Global Oncolytic Adenovirus Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oncolytic Adenovirus Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
